Connect Biopharma Holdings
CNTB
12 hedge funds and large institutions have $4.52M invested in Connect Biopharma Holdings in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 12 → 12 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
1.77% less ownership
Funds ownership: 7.17% → 5.4% (-1.8%)
34% less capital invested
Capital invested by funds: $6.87M → $4.52M (-$2.34M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$20.9K |
| 2 |
KMWM
Keudell/Morrison Wealth Management
Salem,
Oregon
|
+$20.5K |
| 3 |
Morgan Stanley
New York
|
+$5.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.54M |
| 2 |
Renaissance Technologies
New York
|
-$45.4K |
| 3 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$29.7K |
| 4 |
Two Sigma Investments
New York
|
-$18.8K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$11.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
1
BML Capital Management
Zionsville,
Indiana
| $3.11M | -$29.7K | -18,090 | -0.9% |
|
|
UOC
2
UBS O'Connor
Chicago,
Illinois
| $776K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $323K | -$45.4K | -27,600 | -12% |
|
|
4
BlackRock
New York
| $158K | -$1.54M | -936,176 | -90% |
|
|
KMWM
5
Keudell/Morrison Wealth Management
Salem,
Oregon
| $48.9K | +$20.5K | +12,500 | +63% |
|
6
Geode Capital Management
Boston,
Massachusetts
| $42.5K | – | – | – |
|
7
Commonwealth Equity Services
Waltham,
Massachusetts
| $30K | – | – | – |
|
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $19K | +$20.9K | +12,700 | New |
|
|
9
RhumbLine Advisers
Boston,
Massachusetts
| $14.4K | -$11.5K | -7,020 | -42% |
|
|
10
Morgan Stanley
New York
| $5.42K | +$5.86K | +3,568 | New |
|
11
JP Morgan Chase
New York
| $184 | – | – | – |
|
12
Qube Research & Technologies (QRT)
London,
United Kingdom
| $70 | – | – | – |
|
|
13
Two Sigma Investments
New York
| – | -$18.8K | -10,805 | Closed |
|
CNTB Hedge Fund Activity: Q2 2024 in Review
12 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Connect Biopharma Holdings (CNTB) for Q2 2024, worth a combined $4.52M — down 34% from $6.87M a quarter earlier.
Fund positioning in CNTB was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $20.9K. The largest seller was BlackRock, cutting an estimated $1.54M.
- 12 institutional investors held Connect Biopharma Holdings (CNTB) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $4.52M of Connect Biopharma Holdings stock for Q2 2024, down 34% quarter-over-quarter.
- 2 funds opened new Connect Biopharma Holdings positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Connect Biopharma Holdings buyer in Q2 2024 was Royal Bank of Canada, an estimated $20.9K added.
- The largest Connect Biopharma Holdings seller in Q2 2024 was BlackRock, an estimated $1.54M sold.
Based on aggregated 13F filings for Q2 2024.